Phreesia, Inc. (NYSE:PHR) CFO Sells $173,360.84 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 5,771 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $30.04, for a total value of $173,360.84. Following the sale, the chief financial officer now directly owns 105,514 shares of the company’s stock, valued at $3,169,640.56. The trade was a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total value of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total value of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total value of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total value of $22,555.28.
• On Monday, January 6th, Balaji Gandhi sold 3,195 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total value of $85,018.95.

Phreesia Stock Performance

Shares of Phreesia stock traded down $1.20 during trading hours on Thursday, reaching $28.49. The company had a trading volume of 346,852 shares, compared to its average volume of 382,462. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The business has a fifty day simple moving average of $27.14 and a 200 day simple moving average of $23.77. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a market cap of $1.66 billion, a PE ratio of -19.38 and a beta of 0.96.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same period last year, the company earned ($0.58) earnings per share. On average, analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Several large investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its stake in Phreesia by 0.9% during the fourth quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock valued at $1,013,000 after buying an additional 357 shares during the period. NewEdge Advisors LLC raised its position in Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock valued at $107,000 after purchasing an additional 459 shares in the last quarter. Johnson Financial Group Inc. raised its position in Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after purchasing an additional 896 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Phreesia by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in Phreesia by 3.8% during the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after purchasing an additional 1,120 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PHR shares. JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. Citigroup increased their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Robert W. Baird reduced their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, KeyCorp increased their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $31.15.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.